Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2009

Transave and NIAID to Evaluate Antibiotic for Nontuberculous Mycobacteria Lung Infections

  • Transave is working with the NIAID to study Arikace™, a sustained-release formulation of the antibiotic amikacin, in patients with nontuberculous mycobacteria (NTM) lung infections. Under the CRADA, the organizations will collaborate on the planning, design, and implementation of a Phase I trial to evaluate the drug in patients who have failed to respond to standard, guideline-based treatment regimens.

    The study will assess the safety and tolerability of Arikace versus placebo administered once daily for several continuous months using the eFlow® Nebulizer System (PARI Pharma), a portable aerosol delivery system. About 35 patients will be enrolled in the trial to be conducted at the NIH Clinical Center in Bethesda, MD. 

    Positive Phase II results were announced in June 2008 from a trial in European CF patients with Pseudomonas lung infections. Transave also previously completed enrollment in two Phase II trials including an evaluation of Arikace as a treatment for non-CF patients who have bronchiectasis with Pseudomonas lung infections and a U.S. study in CF patients with Pseudomonas lung infections. Arikace has been granted orphan drug status in the U.S. and Europe for the treatment of Pseudomonas infections in patients with CF.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »